Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

DSM invests in biomaterials company Oxford Performance Materials

DSM Coating Resins : 21 June, 2006  (Company News)
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has invested USD 1.2 mln in the biomaterials company Oxford Performance Materials. This investment links on to DSM
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has invested USD 1.2 mln in the biomaterials company Oxford Performance Materials. This investment links on to DSMís innovation ambitions in the emerging business area of biomedical materials, which is an important element of DSMís strategy Vision 2010, Building on Strengths.

OPM markets biocompatible high performance polymers for use in medical device applications such as catheters and implantable devices. OPMís polymers offer advantages over metals in terms of improved biocompatibility, process flexibility, radiolucense and tailored formulations to meet biomechanical and design criteria. Steve Hartig, Vice President EBA Biomedical Materials explains: 'OPMís activities provide useful insight into developments in the field of advanced biomedical polymers, which connects closely to DSMís position in polymers and biomedical applications.'

Medical devices including drug/device combinations are a rapidly growing segment of the health care industry. These innovative therapies are increasingly used in order to bring the therapy or drug as close as possible to the impacted area of the body allowing for faster and more efficient medical treatments. A common theme across these therapies is the importance of materials as a core technology.

Today DSM already offers a number of material products to the healthcare industry like medical coatings and Dyneema Purity for use in surgical implants. In the EBA Biomedical Materials DSM aims to strongly expand this position and develop areas for future growth. Target areas for future innovation are drug delivery systems such as coatings for drug eluting stents and polymeric scaffolds for tissue regeneration. The EBA Biomedical Materials draws upon DSMís expertise in the fields of polymers, coatings and material sciences combined with its strong position in life sciences. DSM actively exploits venturing and licensing opportunities to boost the innovation process in this field and will set up business models that are typical for knowledge-based rather than for production-based businesses, including the licensing of intellectual property.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   ¬© 2012 NewMaterials.com
Netgains Logo